PharmaVoice 10 mar 2026 Executives want in, but researchers want out — how pharma’s US job picture is changing
PharmaVoice 9 mar 2026 The first KRAS drugs have been sluggish on the market. Will the next generation fare better?
PharmaVoice 3 mar 2026 J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks